Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV.
Saved in:
| Title: | Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV. |
|---|---|
| Authors: | Prunas O; Swiss Tropical and Public Health Institute, Basel, Switzerland.; University of Basel, Basel, Switzerland., Willemsen J; Centre for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.; Division of Infectious Diseases, Department of Pediatrics, University Medical Center Utrecht, Utrecht, the Netherlands., Warren JL; Department of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT USA., Bont L; Division of Infectious Diseases, Department of Pediatrics, University Medical Center Utrecht, Utrecht, the Netherlands., Schwartz JL; Department of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA., Atwell J; Medical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, USA., Begier E; Medical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, USA., Dean N; Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA., Hirsch I; Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Karron R; Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD., Klugman K; Director of Pneumonia and Pandemic Preparedness Programs, Bill & Melinda Gates Foundation, Seattle, WA, USA., Kramer R; Sanofi Vaccines, Lyon, France., Leidman E; US Centers for Disease Control and Prevention, Atlanta, GA, USA., Link-Gelles R; US Centers for Disease Control and Prevention, Atlanta, GA, USA., Nair H; Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK., Panozzo CA; Clinical Development, Infectious Diseases, Moderna Therapeutics, Cambridge, MA, USA., Pelfrene E; Office of Vaccines and Therapies for Infectious Diseases, European Medicines Agency, Amsterdam, the Netherlands., Simões EAF; Department of Pediatrics, University of Colorado School of Medicine, Aurora, Department of Epidemiology, Colorado School of Public Health and Samshoma Medical Research Inc, Denver, CO, USA., Smith PG; MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK., Srikantiah P; Bill & Melinda Gates Foundation, Seattle, WA, USA., Sundaram ME; Marshfield Clinic Research Institute, Center for Clinical Epidemiology & Population Health, Marshfield, WI, USA., Thindwa D; Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT USA., Vaughn DW; Bill & Melinda Gates Foundation, Seattle, WA, USA., Wilson E; Clinical Development, Infectious Diseases, Moderna Therapeutics, Cambridge, MA, USA., Zar HJ; Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, and SA-Medical Research Council on Child & Adolescent Health University of Cape Town, South Africa., Pitzer VE; Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT USA., Weinberger DM; Department of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT USA. |
| Source: | Vaccine: X [Vaccine X] 2024 Jun 06; Vol. 19, pp. 100509. Date of Electronic Publication: 2024 Jun 06 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101748769 Publication Model: eCollection Cited Medium: Internet ISSN: 2590-1362 (Electronic) Linking ISSN: 25901362 NLM ISO Abbreviation: Vaccine X Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
